In a first-of-its-kind randomized clinical trial, researchers from the Centre for Addiction and Mental Health and collaborators have shown the benefits of a personalized approach to smoking treatment, based on how quickly smokers break down nicotine in their bodies.
Oh, Canada. In some ways, you’re showing your much bigger neighbor in the south the way forward in taking pharmacy to a higher level of practice. And if we’re smart, we’ll pay attention to the results.
Patients with moderate to severe rheumatoid arthritis who respond to 12 weeks of treatment with a drug made by UCB are more likely to show improvement in their condition in the long run, according to results of a study published in the Journal of Rheumatology.